Erratum: Specific inhibition of phosphodiesterase-4B results in anxiolysis and facilitates memory acquisition (Neuropsychopharmacology (2016) 41 (1080-1092) DOI: 10.1038/npp.2015.240);Specific Inhibition of Phosphodiesterase-4B Results in Anxiolysis and Facilitates Memory Acquisition

Neuropsychopharmacology

Volumn 41, Issue 4, 2016, Pages 1080-1092

  Mcgirr, Alexander ^a,b   Lipina, Tatiana V ^b   Mun, Ho Suk ^b,c   Georgiou, John ^b   Al Amri, Ahmed H ^d,e   Ng, Enoch ^b,c   Zhai, Dongxu ^f   Elliott, Christina ^g   Cameron, Ryan T ^g   Mullins, Jonathan Gl ^h   Liu, Fang ^f   Baillie, George S ^g   Clapcote, Steven J ^d   Roder, John C ^b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e ROYAL HOSPITAL   (Oman)

^f CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; PHOSPHODIESTERASE; PHOSPHODIESTERASE 4B; PHOSPHODIESTERASE IV INHIBITOR; UNCLASSIFIED DRUG; CREB1 PROTEIN, MOUSE; DISC1 PROTEIN, MOUSE; NERVE PROTEIN; PHOSPHODIESTERASE IV; RETINA S ANTIGEN;

ANIMAL EXPERIMENT; ANXIETY DISORDER; ARTICLE; BRAIN FUNCTION; BRAIN REGION; CELL DENSITY; COGNITIVE DEFECT; DENDRITIC SPINE; ENZYME ACTIVE SITE; ENZYME INHIBITION; EX VIVO STUDY; EXPLORATORY BEHAVIOR; FEAR; FEAR MEMORY; FEMALE; FORCED SWIM TEST; GENETIC RISK; HIPPOCAMPUS; HUMAN; HUMAN CELL; LEARNING; LONG TERM POTENTIATION; MALE; MEMORY; MEMORY CONSOLIDATION; MOUSE; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; AMYGDALA; ANIMAL; ANXIETY; BAGG ALBINO MOUSE; C57BL MOUSE; CONDITIONED REFLEX; CYTOLOGY; ENZYMOLOGY; GENETICS; METABOLISM; NERVE CELL; PHOSPHORYLATION; PHYSIOLOGY; TRANSGENIC MOUSE;

AMYGDALA; ANIMALS; ANXIETY; ARRESTINS; BETA-ARRESTINS; CONDITIONING, CLASSICAL; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DENDRITIC SPINES; EXPLORATORY BEHAVIOR; FEAR; FEMALE; HIPPOCAMPUS; MALE; MEMORY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEUROGENESIS; NEURONAL PLASTICITY; NEURONS; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84957442782     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2016.263     Document Type: Erratum

References (66)

1. Ahmed T, Frey JU (2005). Phosphodiesterase 4B (PDE4B) and cAMP-level regulation within different tissue fractions of rat hippocampal slices during long-Term potentiation in vitro. Brain Res 1041: 212-222.
2. Akers KG, Martinez-Canabal A, Restivo L, Yiu AP, De Cristofaro A, Hsiang HL et al (2014). Hippocampal neurogenesis regulates forgetting during adulthood and infancy. Science 344: 598-602.
3. Albensi BC, Oliver DR, Toupin J, Odero G (2007). Electrical stimulation protocols for hippocampal synaptic plasticity and neuronal hyper-excitability: Are they effective or relevant? Exp Neurol 204: 1-13.
4. Baillie GS (2009). Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases. Febs J 276: 1790-1799.
5. Baillie GS, MacKenzie SJ, McPhee I, Houslay MD (2000). Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMPspecific phosphodiesterases. Br J Pharmacol 131: 811-819.
6. Baillie GS, Sood A, McPhee I, Gall I, Perry SJ, Lefkowitz RJ et al (2003). beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-Adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci USA 100: 940-945.
7. Bekinschtein P, Cammarota M, Igaz LM, Bevilaqua LR, Izquierdo I, Medina JH (2007). Persistence of long-Term memory storage requires a late protein synthesis-And BDNF-dependent phase in the hippocampus. Neuron 53: 261-277.
8. Blackwood DH, Fordyce A, Walker MT St, Clair DM, Porteous DJ, Muir WJ (2001). Schizophrenia and affective disorders-cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet 69: 428-433.
9. Cherry JA, Davis RL (1999). Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J Comp Neurol 407: 287-301.
10. Cheung YF, Kan Z, Garrett-Engele P, Gall I, Murdoch H, Baillie GS et al (2007). PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-Terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6). J Pharmacol Exp Ther 322: 600-609.
11. Davis JA, Gould TJ (2005). Rolipram attenuates MK-801-induced deficits in latent inhibition. Behav Neurosci 119: 595-602.
12. de Lima MN, Presti-Torres J, Garcia VA, Guimaraes MR, Scalco FS, Roesler R et al (2008). Amelioration of recognition memory impairment associated with iron loading or aging by the type 4-specific phosphodiesterase inhibitor rolipram in rats. Neuropharmacology 55: 788-792.
13. Fatemi SH, King DP, Reutiman TJ, Folsom TD, Laurence JA, Lee S et al (2008). PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia. Schizophr Res 101: 36-49.
14. Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M et al (2000). Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 28: 41-51.
15. Fujimaki K, Morinobu S, Duman RS (2000). Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressantinduction of BDNF mRNA in rat hippocampus. Neuropsychopharmacology 22: 42-51.
16. Ghavami A, Hirst WD, Novak TJ (2006). Selective phosphodiesterase (PDE)-4 inhibitors: A novel approach to treating memory deficit? Drugs R D 7: 63-71.
17. Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O (2004). Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 114: 1624-1634.
18. Goto T, Shiina A, Yoshino T, Mizukami K, Hirahara K, Suzuki O et al (2013). Identification of the fused bicyclic 4-Amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors. Bioorg Med Chem Lett 23: 3325-3328.
19. Grunwald IC, Korte M, Wolfer D, Wilkinson GA, Unsicker K, Lipp HP et al (2001). Kinase-independent requirement of EphB2 receptors in hippocampal synaptic plasticity. Neuron 32: 1027-1040.
20. Guan F, Zhang C, Wei S, Zhang H, Gong X, Feng J et al (2012). Association of PDE4B polymorphisms and schizophrenia in Northwestern Han Chinese. Hum Genet 131: 1047-1056.
21. Ikeda K, Satake S, Onaka T, Sugimoto H, Takeda N, Imoto K et al (2013). Enhanced inhibitory neurotransmission in the cerebellar cortex of Atp1a3-deficient heterozygous mice. J Physiol 591 (Pt 13): 3433-3449.
22. Kahler AK, Otnaess MK, Wirgenes KV, Hansen T, Jonsson EG, Agartz I et al (2010). Association study of PDE4B gene variants in Scandinavian schizophrenia and bipolar disorder multicenter case-control samples. Am J Med Genet B Neuropsychiatr Genet 153B: 86-96.
23. Kirshenbaum GS, Dawson N, Mullins JG, Johnston TH, Drinkhill MJ, Edwards IJ et al (2013). Alternating hemiplegia of childhood-related neural and behavioural phenotypes in Na+,K+-ATPase alpha3 missense mutant mice. PLoS One 8: e60141.
24. Lakics V, Karran EH, Boess FG (2010). Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 59: 367-374.
25. LeDoux JE (2000). Emotion circuits in the brain. Annu Rev Neurosci 23: 155-184.
26. Lee FH, Fadel MP, Preston-Maher K, Cordes SP, Clapcote SJ, Price DJ et al (2011). Disc1 point mutations in mice affect development of the cerebral cortex. J Neurosci 31: 3197-3206.
27. Li LX, Cheng YF, Lin HB, Wang C, Xu JP, Zhang HT (2011a). Prevention of cerebral ischemia-induced memory deficits by inhibition of phosphodiesterase-4 in rats. Metab Brain Dis 26: 37-47.
28. Li Y, Li H, Liu X, Bao G, Tao Y, Wu Z et al (2009a). Regulation of amygdalar PKA by beta-Arrestin-2/phosphodiesterase-4 complex is critical for fear conditioning. Proc Natl Acad Sci USA 106: 21918-21923.
29. Li YF, Cheng YF, Huang Y, Conti M, Wilson SP, O'Donnell JM et al (2011b). Phosphodiesterase-4D knock-out and RNA interferencemediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling. J Neurosci 31: 172-183.
30. Li YF, Huang Y, Amsdell SL, Xiao L, O'Donnell JM, Zhang HT (2009b). Antidepressant-And anxiolytic-like effects of the phosphodiesterase-4 inhibitor rolipram on behavior depend on cyclic AMP response element binding protein-mediated neurogenesis in the hippocampus. Neuropsychopharmacology 34: 2404-2419.
31. Light KR, Grossman H, Kolata S, Wass C, Matzel LD (2011). General learning ability regulates exploration through its influence on rate of habituation. Behav Brain Res 223: 297-309.
32. Light KR, Kolata S, Hale G, Grossman H, Matzel LD (2008). Upregulation of exploratory tendencies does not enhance general learning abilities in juvenile or young-Adult outbred mice. Neurobiol Learn Mem 90: 317-329.
33. Marchetti C, Tafi E, Middei S, Rubinacci MA, Restivo L, Ammassari-Teule M et al (2010). Synaptic adaptations of CA1 pyramidal neurons induced by a highly effective combinational antidepressant therapy. Biol Psychiatry 67: 146-154.
34. Matzel LD, Townsend DA, Grossman H, Han YR, Hale G, Zappulla M et al (2006). Exploration in outbred mice covaries with general learning abilities irrespective of stress reactivity, emotionality, and physical attributes. Neurobiol Learn Mem 86: 228-240.
35. Menniti FS, Faraci WS, Schmidt CJ (2006). Phosphodiesterases in the CNS: Targets for drug development. Nat Rev Drug Discov 5: 660-670.
36. Millar JK, Pickard BS, Mackie S, James R, Christie S, Buchanan SR et al (2005). DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310: 1187-1191.
37. Mori F, Perez-Torres S, De Caro R, Porzionato A, Macchi V, Beleta J et al (2010). The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D. J Chem Neuroanat 40: 36-42.
38. Murdoch H, Mackie S, Collins DM, Hill EV, Bolger GB, Klussmann E et al (2007). Isoform-selective susceptibility of DISC1/phosphodiesterase-4 complexes to dissociation by elevated intracellular cAMP levels. J Neurosci 27: 9513-9524.
39. Naganuma K, Omura A, Maekawara N, Saitoh M, Ohkawa N, Kubota T et al (2009). Discovery of selective PDE4B inhibitors. Bioorg Med Chem Lett 19: 3174-3176.
40. Numata S, Ueno S, Iga J, Song H, Nakataki M, Tayoshi S et al (2008). Positive association of the PDE4B (phosphodiesterase 4B) gene with schizophrenia in the Japanese population. J Psychiatr Res 43: 7-12.
41. Paspalas CD, Wang M, Arnsten AF (2013). Constellation of HCN channels and cAMP regulating proteins in dendritic spines of the primate prefrontal cortex: potential substrate for working memory deficits in schizophrenia. Cereb Cortex 23: 1643-1654.
42. Perez-Torres S, Miro X, Palacios JM, Cortes R, Puigdomenech P, Mengod G (2000). Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain. J Chem Neuroanat 20: 349-374.
43. Pickard BS, Thomson PA, Christoforou A, Evans KL, Morris SW, Porteous DJ et al (2007). The PDE4B gene confers sex-specific protection against schizophrenia. Psychiatr Genet 17: 129-133.
44. Porteous DJ, Thomson PA, Millar JK, Evans KL, Hennah W, Soares DC et al (2014). DISC1 as a genetic risk factor for schizophrenia and related major mental illness: response to Sullivan. Mol Psychiatry 19: 141-143.
45. Rastogi A, Zai C, Likhodi O, Kennedy JL, Wong AH (2009). Genetic association and post-mortem brain mRNA analysis of DISC1 and related genes in schizophrenia. Schizophr Res 114: 39-49.
46. Reyes-Irisarri E, Perez-Torres S, Miro X, Martinez E, Puigdomenech P, Palacios JM et al (2008). Differential distribution of PDE4B splice variant mRNAs in rat brain and the effects of systemic administration of LPS in their expression. Synapse 62: 74-79.
47. Richter W, Menniti FS, Zhang HT, Conti M (2013). PDE4 as a target for cognition enhancement. Expert Opin Ther Targets 17: 1011-1027.
48. Richter W, Unciuleac L, Hermsdorf T, Kronbach T, Dettmer D (2001). Identification of inhibitor binding sites of the cAMPspecific phosphodiesterase 4. Cell Signal 13: 287-297.
49. Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Laliberte F et al (2002). Deletion of phosphodiesterase 4D in mice shortens alpha(2)-Adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 110: 1045-1052.
50. Rutten K, Wallace TL, Works M, Prickaerts J, Blokland A, Novak TJ et al (2011). Enhanced long-Term depression and impaired reversal learning in phosphodiesterase 4B-knockout (PDE4B (-/-)) mice. Neuropharmacology 61: 138-147.
51. Rutter AR, Poffe A, Cavallini P, Davis TG, Schneck J, Negri M et al (2014). GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognitionenhancing effects without inducing side effects in preclinical species. J Pharmacol Exp Ther 350: 153-163.
52. Saab BJ, Georgiou J, Nath A, Lee FJ, Wang M, Michalon A et al (2009). NCS-1 in the dentate gyrus promotes exploration, synaptic plasticity, and rapid acquisition of spatial memory. Neuron 63: 643-656.
53. Shepherd M, McSorley T, Olsen AE, Johnston LA, Thomson NC, Baillie GS et al (2003). Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform. Biochem J 370(Pt 2): 429-438.
54. Silvestre JS, Fernandez AG, Palacios JM (1999). Effects of rolipram on the elevated plus-maze test in rats: A preliminary study. J Psychopharmacol 13: 274-277.
55. Siuciak JA, Chapin DS, McCarthy SA, Martin AN (2007). Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology (Berl) 192: 415-424.
56. Siuciak JA, McCarthy SA, Chapin DS, Martin AN (2008). Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology (Berl) 197: 115-126.
57. Slipczuk L, Tomaiuolo M, Garagoli F, Weisstaub N, Katche C, Bekinschtein P et al (2013). Attenuating the persistence of fear memory storage using a single dose of antidepressant. Mol Psychiatry 18: 7-8.
58. Smith DL, Pozueta J, Gong B, Arancio O, Shelanski M (2009). Reversal of long-Term dendritic spine alterations in Alzheimer disease models. Proc Natl Acad Sci USA 106: 16877-16882.
59. Stupien G, Florian C, Roullet P (2003). Involvement of the hippocampal CA3-region in acquisition and in memory consolidation of spatial but not in object information in mice. Neurobiol Learn Mem 80: 32-41.
60. Sung BJ, Hwang KY, Jeon YH, Lee JI, Heo YS, Kim JH et al (2003). Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature 425: 98-102.
61. Tomppo L, Hennah W, Lahermo P, Loukola A, Tuulio-Henriksson A, Suvisaari J et al (2009). Association between genes of disrupted in schizophrenia 1 (DISC1) interactors and schizophrenia supports the role of the DISC1 pathway in the etiology of major mental illnesses. Biol Psychiatry 65: 1055-1062.
62. Tully T, Bourtchouladze R, Scott R, Tallman J (2003). Targeting the CREB pathway for memory enhancers. Nat Rev Drug Discov 2: 267-277.
63. Vyas A, Kim SK, Giacomini N, Boothroyd JC, Sapolsky RM (2007). Behavioral changes induced by Toxoplasma infection of rodents are highly specific to aversion of cat odors. Proc Natl Acad Sci USA 104: 6442-6447.
64. Zhang HT (2009). Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. Curr Pharm Des 15: 1688-1698.
65. Zhang HT, Crissman AM, Dorairaj NR, Chandler LJ, O'Donnell JM (2000). Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology 23: 198-204.
66. Zhang HT, Huang Y, Masood A, Stolinski LR, Li Y, Zhang L et al (2008). Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). Neuropsychopharmacology 33: 1611-1623.